 SUZHOU, China, March 17, 2021 PRNewswire -- WuXi Biologics WuXi Bio 2269.HK, a global company with leading open-access biologics technology platforms, today announced it has entered into a purchase agreement with CBC Group CBC, a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90 interest of CMAB Biopharma Group CMAB. The transaction is expected to close in the second quarter of 2021. 